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JacobD. deBoer,MD,1,2 Agita Strelniece,3Marieke van Rosmalen,MD,1 Erwin de Vries,1 Dirk Ysebaert, MD, PhD,4
Markus Guba, MD, PhD,5 Andries Erik Braat, MD, PhD,2 and Undine Samuel, MD, PhD1Background. Both University of Wisconsin (UW) and histidine-tryptophan-ketoglutarate (HTK) solutions are currently used in
the Eurotransplant region for preservation of liver allografts. Previous studies on their effect have led to a lot of discussion. This
study aims to compare the effect of HTK and UW on graft survival. Methods. First liver transplantations in recipients 18 years
or older from January 1, 2007, until December 31, 2016, were included. Graft survival was compared for livers preserved with
HTK and UW at 30 days, 1, 3, and 5 years. Multivariable analysis of risk factors was performed and outcome was adjusted for
important confounders.Results.Of all 10628 first liver transplantations, 8176 (77%) and 2452 (23%) were performed with livers
preserved with HTK and UW, respectively. Kaplan-Meier curves showed significant differences in graft survival between HTK and
UW at 30 days (89% vs 93%, P=<0.001), 1 year (75% vs 82%, P=<0.001), 3 years (67% vs 72%, P<0.001), and at 5 years
(60% vs 67%, P<0.001). No significant differences in outcome were observed in separate analyses of Germany or non-German
countries. In multivariable analysis, UW was associated with a decreased risk of graft loss at 30 days (HR 0.772, P=0.002) and
at 1 year (0.847 (0.757-0.947). When adjusted for risk factors, no differences in long term outcome could be detected.
Conclusions. Because the use of preservation fluids is clustered geographically, differences in outcome by preservation fluids
are strongly affected by regional differences in donor and recipient characteristics. When adjusted for risk factors, no differences in
graft survival exist between transplantations performed with livers preserved with either HTK or UW.
(Transplantation 2018;102: 1870–1877)Ischemic injury sustained during organ preservation influ-ences posttransplantation outcomes in an important way.
Throughout the process of organ preservation, preservation
fluids are used. In the donor, the liver is perfused with cold
preservation fluid after cross-clamping of the aorta. It is then
packed in a sterile bag filled with this same fluid in a boxwith
ice after hepatecomy.1 In the transplant hospital, the organ is
perfused before transplantation using the same preservation
fluid. Almost all livers within Eurotransplant (ET) are pre-
served by this “cold storage.”Other preservation techniques,Received 22 February 2018. Revision received 18 May 2018.
Accepted 29 May 2018.
1 Eurotransplant International Foundation, Leiden, The Netherlands.
2 Department of Surgery, Leiden University Medical Center, Leiden, The
Netherlands.
3 Biostatistical Department, Eurotransplant International Foundation, Leiden, The
Netherlands.
4 Department of Hepatobiliary, Transplantation and Endocrine Surgery, Antwerp
University Hospital, University of Antwerp, Belgium.
5 Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery,
Hospital of the University of Munich, Munich, Germany.
The authors declare no funding or conflict of interest.
1870 www.transplantjournal.com
Copyright © 2018 Wolters Kluwersuch as machine perfusion, are currently only performed in
an experimental way.
Several preservation fluids are used within the ET region
although most countries use either University of Wisconsin
(UW) solution or histidine-tryptophan-ketoglutarate (HTK)
solution.2 The choice of preservation fluid is thought to be
important for outcome and a difference in effect on outcome
has often been studied. First, studies on the topic could not
detect significant differences in short- and long-term patient
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TABLE 1.
Studies on the use and effect of perfusion fluids in deceased donor liver transplantation






30 d 3 mo 6 mo 1 y 3 y 5 y Best
Adam et al8 2015 AJT Retrospective study on the ELTR database HTK 8696 77% 69% 64% UW
UW 24562 83% 75% 69%
CE 7756 82% 73% 68%
IGL 1855 82% 75% 68%
Kaltenborn et al9 2014 BMC gastroenterology Double-center, retrospective study HTK 1838 No effect in 3 month graft survival,
HTK beneficial on long term
graft survival in univariate but
not in multivariable analysis
HTK
UW 1314
Stewart et al10 2009 AJT Retrospective study on the UNOS database HTK 4755 HTK vs UW, OR 1.2 (1.04-1.39,
P < 0.012) on early graft




Rayya et al7 2008 Transplant procedure Single-center, retrospective study HTK 69 90% 71% 71% UW
UW 68 90% 78% 75%
Mangus et al6 2008 Liver transplantation Single-center, retrospective study in ECD livers HTK 204 89% 84% HTK
UW 231 88% 83%
Meine et al3 2006 Transplant procedure Single-center, randomized, prospective study HTK 37 No significant differences in




Avolio et al5 2006 Transplant procedure Single-center study HTK 14 86%
UW 21 81%
Mangus et al4 2006 Liver transplantation Single-center, retrospective study HTK 174 92% 86% 81% UW
UW 204 92% 86% 82%
Erhard et al2 1994 Transplant Int. Prospective, randomized study HTK 30 87% 77% HTK
UW 30 80% 74%
© 2018 Wolters Kluwer de Boer et al 1871of the frequent single-center design and low numbers of in-
cluded transplantations. A larger study by Stewart et al10
showedHTK to be associated with a higher risk of early graft
loss (<30 days) as compared with UW in the United Network
for Organ Sharing (UNOS) database. It contributed to a
gradual change to UW although some centers prefer HTK
for the lower viscosity and lower costs.
More recent studies of Kaltenborn et al9 and Adam et al8
presented conflicting results on the issue. Kaltenborn showed
only minimal differences between HTK and UW, whereas
Adam et al found HTK to be associated with a significant in-
creased risk of long-term graft loss (at least up to 5 years) as
compared with UW in the European Liver Transplant Regis-
try (ELTR).8 Several remarks and concerns with the design of
the study and its conclusions were placed by Nashan et al.11
Most important concerns were with including living dona-
tion, insufficient risk adjustment and the overrepresentation
of German livers in the HTK group. Germany uses HTK ex-
clusively and it has a model for end-stage liver disease
(MELD)-based allocation combined with one of the lowest
donor rates of Europe.12 The difference in long-term out-
come that was attributed to HTK in this study might rather
reflect inferior outcomes in general in Germany. In response,
Adam et al published an analysis without living donors and
German centers and more recently, an analysis based on pro-
pensity score matching.8,13 This analysis matched patients on
ABO compatibility; recipient ischemic time of 6 hours or lon-
ger; sex; study period (2003-2007 vs 2008-2012); recipient
age, 60 years or older, donor age, 55 years or older; whole
liver; urgency of transplantation; hepatocellular carcinoma;Copyright © 2018 Wolters Kluwer Hrecipient HIV status; and centers performing more than 10
liver transplantations from living donors. Although an asso-
ciation betweenHTK and graft loss could be seen, we believe
that interregional differences in donor, transplant, and recip-
ient characteristics were insufficiently taken into account.
This study aims to evaluate the effect of HTK and UWon
short- and long-term outcomes after liver transplantation in
the Eurotransplant region, with adequate adjustment for (re-
gional) differences in donor, transplant, and recipient factors.PATIENTS AND METHODS
Data Selection
All first transplantations from deceased donor livers per-
formed in adult recipients (≥18 years) from January 1,
2007, until December 31, 2016, were included. Transplanta-
tions with livers from donors after circulatory death (DCD)
(n = 771), split allografts (n = 380) and allografts from do-
nors outside of Eurotransplant were excluded. When in-
formation on the used preservation fluids was missing
(n = 160) or when preserved with other preservation fluids
than HTK or UW fluid (Celsior n = 18, Eurocollins = 1,
IGL-1 n = 79 and other n = 216) transplantations were also
excluded as well as transplantations performed in patients
with a high-urgency status (n = 888), with a combination
other than liver/kidney and transplantations performed
in Göttingen.14 Transplantations were categorized in ei-
ther HTK or UW according to the preservation fluid that
was used during procurement and subsequent transport.ealth, Inc. All rights reserved.
FIGURE 1. The use of HTK and UW in the Eurotransplant region.
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work Information System and ET Liver Registry up to
September 2017. All data were anonymized for transplant
center and patient related data with exception of country.
The study protocol was approved by the Eurotransplant Liver
Intestine Advisory Committee, and no ethical statement was
required according to European guidelines and Dutch law.
Data Analysis
Laboratory values were converted to standardized
units and in case of missing values <2%, median values
were used; gamma-glutamyl-transpeptidase (GGT) 38 U/L
(1.8%) and recipient body mass index (BMI) 25.8 (0%).
The Eurotransplant-Donor Risk Index (ET-DRI)15 was cal-
culated for all transplanted livers and the simplified recipient
risk index (sRRI)16 was calculated for all recipients based on
most recent laboratory MELD score before transplantation.
With the ET-DRI and sRRI the donor-recipient model (DRM)
was calculated for all transplantations.17 Serum creatinin value
was set at 4 mg/d therapy according to ET guidelines for pa-
tients receiving renal replacement, MELD score was rounded
to the nearest whole value (range, 6-40). Donor hepatitis C
antibody (HCVAb), donor hepatitis B core antibody (HBcAb),
recipient HCVAb, dialysis of the recipient before transplanta-
tion and a history of diabetes in the donor were considered
negative if not tested or missing. Rescue allocation is a
center-oriented allocation after patient-oriented allocation and
is started for short allocation time or medical reasons. Clinical
characteristics were summarized by median and 25% and
75% interquartile ranges (IQR) and number and percentage
(N/%) for respectively continuous and categorical variables.
Numerical and categorical factors between groups were
compared using Kruskall-Wallis and χ2 tests.
Outcome Measures
Primary outcomes used in the analyses were 30 days, 1-,
3-, and 5-year non–death-censored graft survival. Secondary
outcomes were 30 days, 1-, 3-, and 5-year patient survival
(PS). Graft survival was defined as the period between date
of transplantation and date of retransplantation or patient
death. Patient survival was defined as the period between
date of transplantation and date of patient death. Outcome
was analyzed by Kaplan Meier analysis and log-rank tests
when stratified by preservation fluid category (HTK, UW).
Results were also stratified for transplantation region and
preservation fluid (Germany+HTK, Germany+UW and
non-Germany+HTK, non-Germany+UW).
Risk Factors
To identify risk factors associated with graft survival, mul-
tivariable analysis was performed in a Cox regression analy-
sis (backward selection) for all transplantations and included
factors described to be associated with graft survival.15,17-19
These factors included donor age, cause of death, sex, BMI,
latest GGT, HBcAb, HCVAb, history of diabetes, Recipient
age, sex, BMI, laboratory MELD score at transplantation,
etiology of primary liver disease, liver/kidney combination,
dialysis before transplantation, total ischemic time, rescue al-
location, allocation region (local, regional, extraregional),
and year of transplantation (continuous). Graft survival
was then adjusted for all risk factors associated with 5-year
graft survival in Germany, non-German countries and all
transplantations. A potential effect of preservation fluids inCopyright © 2018 Wolters KluwerHCC patients or in livers with longer cold ischemic times
was described in literature.8 This potential relation was ana-
lyzed with Kaplan-Meier analysis and in a Cox-regression
analysis when adjusted for risk factors.
For all analyses a Wald P value less than 0.05 was consid-
ered significant. Survival analyses were performed using
Kaplan-Meier survival models and multivariable analyses
were performed using Cox regression models. All analyses
were performed with SPSS (version 24.0).
RESULTS
Within the study period, 10628 first liver transplantations
were included. Median donor age of all transplantations was
55 years old (IQR, 45-67) and median donor BMI 26 (IQR,
24-28). Cerebrovascular accident was the most frequent
cause of death (62%) followed by trauma (20%). Near half
of donors was allocated extraregionally (46%) and median
ET-DRI was 1.84. Most recipients were male (70%) and
had a median age 56 years old and median BMI of 25.
Transplanted recipients had a median laboratory MELD
score of 16 and a median match MELD score of 24. Alco-
holic disease was most frequent primary diagnosis (27%)
followed by malignant disease (25%) and other cirrhosis
(14%). The majority of transplantations was performed in
Germany (62%) followed by Belgium (12%) and Austria
(10%). Median sRRI was 1.86 and median DRM was 2.77.
Preservation Fluid Category
Of all transplantations, 8176 (77%) and 2452 (23%)were
performed with livers preserved with HTK and UW, respec-
tively. The relative use of UW decreased from 36% in 2007
to 18% in 2016, whereas the use of HTK increased from
64% to 82% (Figure 1). Within donor countries strong pref-
erence for either HTK or UW during procurement was seen.
HTK is preferred in Hungary (100%), Germany (98%),
Slovenia (97%) and Austria (84%), whereas UW is preferred
in The Netherlands (98%), Croatia (83%), Belgium (73%)
and, with very small numbers, Luxembourg (100%).
Median donor age and BMI were significantly higher in
the HTK group as compared with the UWgroup (56 years vs
55 years, P < 0.001) and (26 years vs 25 years, P < 0.001), re-
spectively. Cause of death of the donor was significantly Health, Inc. All rights reserved.
TABLE 2.
















Donor age, y 56 (45-67) 55 (43-65) <0.001
Height, cm 174 (165-180) 174 (167-180) 0.097
Weight, kg 80 (70-90) 76 (68-85) <0.001
BMI 26 (24-28) 25 (23-28) <0.001
Last GGT, U/L 43 (22-99) 31 (17-62) <0.001
Sex (male) 4445 (54) 1366 (56) 0.241
Cause of death <0.001
Anoxia 1020 (13) 82 (3)
Circulational 113 (1) 158 (6)
CNS tumor 44 (1) 19 (1)
CVA/stroke 5129 (63) 1484 (61)
Trauma 1426 (17) 648 (26)
Other 443 (5) 61 (3)
Diabetes, y 816 (10) 173 (7) <0.001
Transplant factor
Total ischemic time, h 8.6 (6.3-11.0) 7.3 (5.0-9.6) <0.001
Allocation region <0.001
Local 1980 (24) 1004 (41)
Regional 1902 (23) 892 (36)
Extraregional 4294 (53) 556 (23)
Rescue (yes) 2613 (32) 389 (16) <0.001
Country <0.001
Germany 6147 (75) 463 (19)
Hungary 221 (3) 11 (0)
The Netherlands 124 (2) 465 (19)
Belgium 476 (6) 752 (31)
Croatia 196 (2) 593 (24)
Slovenia 149 (2) 9 (0)
Austria 863 (11) 159 (7)
ET-DRI 1.90 (1.59 -2.24) 1.66 (1.40-1.92) <0.001
Recipient factor
Age, y 56 (49-62) 57 (49-62) 0.093
Height, cm 174 (168-180) 173 (167-180) 0.003
Weight, kg 80 (69-90) 78 (68-90) 0.019
BMI 26 (23-29) 26 (23-29) 0.390
Laboratory MELD 16 (11-27) 16 (11-23) 0.001
Match MELD 25 (16-31) 22 (17-27) <0.001
Exceptional MELD (yes) 2753 (34) 790 (32) 0.181
Sex (male) 5759 (70) 1696 (69) 0.228
Dialysis pretransplant 1002 (12) 157 (6) <0.001
Primary diagnosis <0.001
Metabolic 264 (3) 91 (4)
Acute 158 (7) 28 (1)
Cholestatic 906 (10) 267 (11)
Alcoholic 2112 (24) 716 (29)
Malignant 2060 (24) 628 (26)
HBV 316 (4) 94 (4)
HCV 867(10) 211 (9)
Other cirrhosis 1146 (13) 295 (12)









<15 3515 (43) 1040 (42)
15-25 2446 (30) 930 (38)
25-35 1136 (14) 329 (13)
35+ 1079 (13) 153 (6)
sRRI 1.87 (1.58-2.23) 1.86 (1.58-2.17) <0.001
DRM 2.85 (2.31-3.51) 2.56 (2.09-3.08) <0.001
© 2018 Wolters Kluwer de Boer et al 1873
Copyright © 2018 Wolters Kluwer Hdifferent between both groups (P < 0.001); less trauma
(17% vs 26%) and more often anoxia (13% vs 3%) were
registered as cause death in the HTK group. Total ischemic
times were longer in the HTK group in comparison to the
UW group (8.6 hours vs 7.3 hours) and HTK livers were
more often accepted in rescue allocation (32% vs 16%,
P < 0.001). The median ET-DRI was significantly higher in
the HTK group (1.90 vs 1.66, P < 0.001).
Recipient age and BMI were not different in both the UW
and HTK group with a median of 56 years old (P = 0.093)
and BMI of 26 (P = 0.390), respectively. Although both
groups had a similar median laboratory MELD score, the
distribution was not equal (P < 0.001). As compared with
the UW group, the HTK group has a higher proportion of
transplanted MELD 25-35 (14% vs 13%) and MELD 35+
recipients (13% vs 6%). Also, the match MELD did vary be-
tween HTK and UW (25 vs 22, P < 0.001). Median sRRI
showed onlyminor differences, whereas theDRMwas signif-
icantly higher in theHTKgroup 2.85 versus 2.56 (P < 0.001),
data shown in Table 2.
Outcome
For all transplantations, graft survival at 30 days, 1, 3 and
5 years was 90%, 77%, 68%, and 62%, respectively. Graft
survival was significantly better in the UW group as com-
pared with HTK at 30 days (93% vs 89%, P = <0.001),
1 year (82% vs 75%, P = <0.001), 3 years (72% vs 67%,
P < 0.001), and at 5 years (67% vs 60%, P < 0.001), as
shown in Figure 2A. Similar differences were found in PS;
transplantations with UW-preserved livers showed better PS
as compared with HTK at 30 days (95% vs 93%,
P = <0.001), 1 year (86% vs 79%, P = <0.001), 3 years
(78% vs 71%, P < 0.001), and at 5 years (72% vs 65%,
P = <0.001), as shown in Figure 2B.
Within Germany, 6174 transplantations were performed
with HTK and 463 with UW. In non-German countries,
2029 and 1989 transplantations were performed with
HTK- and UW-preserved livers, respectively. Outcome
stratified for transplantation region (Germany/non-Germany)
and preservation fluid (HTK/UW) showed significantly
lower overall graft survival in Germany.Within both regions,
a trend for a slightly higher graft survival on short term was
seen for UW-preserved livers as compared with HTK livers.
On long-term, HTK livers showed a trend toward better
graft survival. This was observed in Germany at 30 days
(HTK 87% vs UW 88%), 1 year (HTK, 72% vs UW,
73%), 3 years (HTK 64% vs UW 64%), and at 5 years
(HTK, 57%vsUW, 56%). In non-Germany this was also ob-
served at 30 days (HTK 93%vs 94%), 1 year (HTK, 83% vsealth, Inc. All rights reserved.
FIGURE 2. Kaplan-Meier survival analysis by preservation fluid (n = 10628). A, Graft survival. B, Patient survival.
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(70% vs 70%) (data shown in Figure 3). Differences in out-
come within both regions were not statistically significant
at any time point.Risk Factors
In multivariable analysis, donor age, total ischemic time,
donor last GGT, a history of diabetes in the donor, allocation
region, rescue, recipient age, sex, etiology of liver disease,
dialysis before transplantation, laboratory MELD score
and year of transplantation were associated with 5-year
graft survival. An association between outcome and pres-
ervation fluids could only be detected on short-term. UW
was associated with a decreased risk of graft loss at 30 days
(hazard ratio [HR], 0.762; 95% confidence interval [CI],
0.643-0.902; P = 0.002) and at 1 year (HR, 0.835; 95%
CI, 0.746-0.0.934; P = 0.002), data are shown in Table 3.
When adjusted for all risk factors associated with 5-years
graft survival, no difference could be detected between
both preservation fluids in transplantations performed in
Germany (P = 0.572) (Figure 4A) or non-Germany (P = 0.522)
(Figure 4B). In all transplantations, also no difference in long-
term outcome could be shown (data are shown in Figure 4C).FIGURE 3. Kaplan Meier survival analysis of graft survival by
preservation fluid and transplant region (Germany vs non-Germany),
(n = 10628).Risk Groups
Of all transplantations, 3527 (33%) of patients had a reg-
istered HCC. Patients with HCC had lower graft survival
when transplanted with a liver preserved with HTK
(n = 2747) as compared with livers preserved with UW
(n = 780) at 30 days (90% vs 93%, P = 0.013) and at 1 year
(77%vs 81%,P = 0.006).When adjusted for other risk factors,
a potential effect of HTKorUWinHCCpatientswas not ob-
served at 30 days (P = 0.557) or at 1 year (P = 0.424).
When transplantations were stratified according to the
ELTR total ischemic times categories, 3 groupswere identified;
livers transplanted with <=6 hours (n = 2700), 6-12 hours
(n = 6231) and > =12 hours (n = 1697) of cold ischemic time.
Only in transplantations performed with livers with 6 to
12 hours of cold ischemic time a statistically significant differ-
ence betweenHTK and UW could be observed (60% vs 69%,
P < 0.001) (data are shown in Figure S1a-c, SDC, http://links.
lww.com/TP/B622). When adjusted for other risk factors, or
when analyzed per region (Germany vs non-Germany) this po-
tential negative impact ofHTK in livers with longer cold ische-
mic times was not observed (data are shown in Figure S2-3a,
b, c, SDC, http://links.lww.com/TP/B622).Copyright © 2018 Wolters KluwerDISCUSSION
This study shows that HTK is used in the majority of or-
gan transplantations within Eurotransplant. The use of
HTK is increasing, in contrast to UW. Overall graft sur-
vival is lower for livers preserved with HTK, but these re-
sults are strongly affected by regional differences in donor,
recipient and transplant characteristics. When adjusted for
these risk factors, no difference between HTK and UW could
be observed.
The issue of preservation fluids remains an important
point of discussion in liver transplantation. Although evi-
dence is still considered nonconclusive, different preservation
fluids are currently used. This study shows that although UW
is internationally considered the golden standard, the relative
use of UWwithin ET is decreasing, whereas the use ofHTK is
increasing. To compare the effect of both preservation fluids,
we have tried to ensure a homogenous study population. We
have excluded all pediatric recipients, those receiving living
related livers, livers from DCD donors, split livers and trans-
plantations in high-urgent patients. Even with these strict in-
clusion criteria, this study includes a sufficiently high number
of transplantations to detect minor differences in outcome
and to perform an adequatemultivariable analysis. The unfa-
vorable characteristics of the group of livers preserved with
HTK are likely to have contributed to the inferior graft sur-
vival and PS.We have therefore separated our analysis per re-
gion, and have adjusted outcome for risk factors to interpret
the differences in graft survival and PS. The high complete-
ness for important data like total ischemic times and MELD Health, Inc. All rights reserved.
TABLE 3.
Multivariable analysis of factors associated with graft survival
30 d 1 y 3 y 5 y
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Donor factor
Preservation fluid: (HTK) UW 0.762 (0.643-0.902) 0.002 0.835 (0.746-0.934) 0.002 a a
Age, y * 1.007 (1.004-1.009) <0.001 1.009 (1.006-1.011) <0.001 1.009 (1.006-1.011) <0.001
Total ischemic time, h 1.031 (1.015-1.047) <0.001 1.026 (1.015-1.037) <0.001 1.017 (1.007-1.026) 0.001 1.016 (1.007-1.025) 0.001
Last GGT 1.001 (1.001-1.002) <0.001 1.001 (1.000-1.001) 0.006 1.000 (1.000-1.001) 0.020 1.000 (1.000-1.001) 0.016
BMI 1.013 (1.000-1.027) 0.050 a a a
Diabetes: (no) yes 1.299 (1.076-1.570) 0.007 1.214 (1.065-1.385) 0.004 1.231 (1.097-1.382) <0.001 1.207 (1.080-1.348) 0.001
Allocation (local) a 0.039 0.003 0.001
Regional a 1.077 (0.954-1.215) 0.230 1.078 (0.972-1.196) 0.154 1.074 (0.974-1.185) 0.151
Extraregional a 1.158 (1.033-1.297) 0.012 1.182 (1.072-1.303) 0.001 1.190 (1.085-1.305) <0.001
Rescue: (no) yes 1.345 (1.159-1.560) <0.001 1.212 (1.091-1.346) <0.001 1.218 (1.113 -1332) <0.001 1.219 (1.121-1.326) <0.001
Recipient factor
Age a 1.011 (1.006-1.015) <0.001 1.012 (1.007-1.016) <0.001 1.011 (1.008-1.015) <0.001
Sex: (female) male a 1.143 (1.040-1.256) 0.005 1.177 (1.083-1.280) <0.001 1.183 (1.092-1.280) <0.001
BMI 1.016 (1.003-1.029) 0.017 a a a
Etiology (metabolic) 0.002 0.005 <0.001 <0.001
Acute 1.897 (1.206-2.984) 0.006 1.389 (0.987-1.954) 0.059 1.372 (1.008-1.866) 0.044 1.398 (1.035-1.889) 0.029
Cholestatic 1.103 (0.751-1.622) 0.616 1.135 (0.871-1.480) 0.348 1.057 (0.836-1.336) 0.646 1.102 (0.877-1.383) 0.404
Alcoholic 0.918 (0.642-.1.313) 0.641 0.990 (0.773-1.267) 0.935 0.926 (0.745-1.152) 0.491 0.990 (0.802-1.223) 0.928
Malignant 1.016 (0.704-1.466) 0.932 1.074 (0.832-1.385) 0.585 1.116 (0.894-1.394) 0.332 1.195 (0.964-1.481) 0.105
HBV 1.023 (0.653-1.602) 0.921 0.872 (0.634-1.201) 0.402 0.887 (0.672-1.171) 0.399 0.913 (0.698-1.194) 0.505
HCV 1.119 (0.764-1.640) 0.563 1.271 (0.978-1.652) 0.073 1.408 (1.120-1.769) 0.003 1.476 (1.183-1.843) 0.001
Other cirrhosis 0.943 (0.648-1.372) 0.758 1.010 (0.780-1.308) 0.940 1.002 (0.798-1.258) 0.986 1.052 (0.843-1.312) 0.655
Other/unknown 1.283 (0.816-2.016) 0.280 0.986 (0.706 -1.378) 0.936 0.786 (0.581-1.062) 0.117 0.823 (0.616-1.098) 0.186
SLK (yes) 0.578 (0.371-0.901) 0.016 0.748 (0.567-0.986) 0.039 a a
Dialysis pretransplant (no) yes 1.417 (1.153-1.742) 0.001 1.489 (1.296-1.709) <0.001 1.231 (1.097-1.382) <0.001 1.402 (1.246-1.578) <0.001
LabMELD (<15) <0.001 <0.001 <0.001 <0.001
≥ 15 and < 25 1.044 (0.889-1.226) 0.598 1.083 (0.970-1.209) 0.158 1.041 (0.947-1.143) 0.405 1.042 (0.954-1.138) 0.363
≥ 25 and < 35 1.356 (1.100-1.671) 0.004 1.580 (1.374-1.817) <0.001 1.434 (1.268-1.623) <0.001 1.347 (1.196-1.516) <0.001
≥ 35 1.776 (1.403-2.248) <0.001 1.976 (1.683-2.320) <0.001 1.799 (1.560-2.075) <0.001 1.705 (1.487-1.956) <0.001
Year of transplantation (2007) 0.975 (0.954-0.998) 0.030 0.979 (0.964-0.995) 0.009 0.984 (0.970-0.997) 0.984 0.985 (0.972-0.999) 0.033
aNo statistical significance and not in the equation.
The following factors were not statistically significantly associated with outcome at the measured time points: donor sex, cause of death, HBcAb, HCVAb, recipient sex, HCVAb.
© 2018 Wolters Kluwer de Boer et al 1875score add to the reliability of our findings. Although per-
formed with care, risk adjustment may still not be sufficient
as is inherent to the retrospective design. We considered graft
survival as primary outcome and did not have information
on biliary complications or early bile production. This is a
potential limitation, because some studies found suggestions
for more posttransplantation bile production and less biliary
complications in livers that were preserved with HTK.20
However, biliary complications will likely also affect graft-
survival in the long run.
The presented results of inferior unadjusted graft survival
between HTK and UW are in line with the previously pub-
lished study by the ELTR.8 The ELTR study attributed this in-
ferior long-term outcome to the use of HTK. Interesting,
because the risk of HTK on graft loss was one of the lowest
of all risk factors and only just statistically significant (risk ratio
1.1, P = 0.02) in over 34500 transplantations.8 Based on our
findings, differences in long-term outcome in particular, are
more likely to reflect differences in donor, recipient and trans-
plant risks than an effect of the preservation fluid itself. When
these differences are adequately taken into account no statisti-
cally significant difference could be detected between HTKCopyright © 2018 Wolters Kluwer Hand UW. This finding is in accordance to other studies that
could not show any significant differences between HTK and
UW.2-7 Although this could be a result of an inadequate power
due to small numbers, also Kaltenborn et al9 neither have
shown a difference in risk between both fluids despite a sizeable
data set (summary in Table 1). A slightly better short term graft
survival in livers preserved with UW, as reported by Stewart
et al,10 may be present according to the risk adjusted survival
in non-German countries (Figure 3B).
Some studies have also described a more pronounced ef-
fect of preservation fluids in several subgroups. This would
affect livers from DCD donors,10 livers with total ischemic
times longer than 12 hours,8 patients with a HCC8 and split
liver allografts.8 A potential difference in DCD donors and
split procedures could not be analyzed because these were
excluded in this study. Differences in the other mentioned
subgroups (categorical total ischemic time groups, HCC
recipients) were not confirmed in this study or did not persist
when adjusted for other risk factors.
To correctly interpret differences in outcome between sev-
eral preservation fluids, the hypothesized causative pathway
is important. The mechanism through which HTK wouldealth, Inc. All rights reserved.
FIGURE 4. Risk adjusted graft survival. A, Germany adjusted for all separate risk factors. B, Non-Germany adjusted for all separate risk fac-
tors. C, All transplantations adjusted for all separate risk factors.
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lated to differences in composition and viscosity2 which
might lead to different effects in liver cell volume, efficiency
of washout or to the presence of antioxidant agents.21,22
These effects would, in theory, especially affect short term
graft survival.
The differences in donor, transplant and patient character-
istics between HTK and UWare primarily a result of the na-
tional choice of preservation fluids. Germany, for example,
used HTK in 97% of all procurements and in 93% of their
transplantations (the difference is because of international
exchange within Eurotransplant). When compared with all
HTK transplantations in Eurotransplant, 75% of all HTK-
preserved livers are transplanted in Germany. A country that
has been struggling with one of the lowest DBD donor rates
in Europe12 and has implemented a MELD based allocation
system. Both are likely to impact posttransplantation out-
come in a negative way (Figure 4). Because of the low dona-
tion rates, limits for liver allografts have been stretched and
liver grafts are in general of lower quality; higher donor
age, lab values and BMI. Also, because of the shortage of
grafts, the waiting list expands and recipients will only be
able to receive an offer when their MELD-score raises.23
For this reason, outcome was stratified for Germany ver-
sus all other countries. It is therefore interesting, that trans-
plantations with HTK livers showed a trend for similar or
better graft survival as compared with UWin both regions al-
though this difference was not statistically significant. This
statistical phenomenon where findings in subgroups are ap-
parently contradictory to overall results is called a Simpson’s
paradox. It can exist when different sample sizes are com-
pared of groups with different outcome. In this case, because
of discrepancies in the use of preservation fluids between
countries with different posttransplantation outcome. The
latter affects outcome of UW livers in Germany: Germany al-
most exclusively uses HTK so livers perfused with UW areCopyright © 2018 Wolters Kluwerlikely to originate from other ET countries. This is the case
for livers that were not accepted for transplantation in the
donor country.
The significant differences in outcome within Eurotransplant
are also observed when results from ETare compared with the
United States. The presented 1-year graft survival rates in
non-German countries of about 83% are significantly lower
than the approximately 90% 1-year graft survival for first
liver transplantations in the United States in 2016.24 We be-
lieve that a difference in liver quality between ET and the
US attributes to this difference in outcome. This difference
in donor quality was shown by Blok et al in 201225 and is ev-
ident for donor age; about 66% of all livers used for a trans-
plant in the United States in 2016 were from donors younger
than 50 years old24 as compared with 36% in ET (median
age, 55 years).23 This might be a result of regulation on cen-
ter outcome as is done in the United States or by an assumed
higher shortage of organs in ET. Regardless of the reason(s),
the difference in donor quality shows that centers in ET have
expanded their criteria for acceptable donors to increase the
number of patients that can be transplanted and to decrease
waiting list mortality. This strategy, however, comes at the
cost of slightly inferior posttransplantation outcome.
In deciding what preservation fluid to use, the experience
of surgeon and center should be themost important consider-
ation. Our results indicate that no significant difference exists
between both preservation fluids. Other aspects, like the
lower viscosity, which is often appreciated by clinicians and
the lower costs associated with the use of HTK might then
also be taken into account.CONCLUSIONS
The use of preservation fluids differs significantly per
country within the Eurotransplant region. Histidine-
tryptophan-ketoglutarate is being used in the majority Health, Inc. All rights reserved.
© 2018 Wolters Kluwer de Boer et al 1877of liver transplantations and its use is increasing, in contrast
to the use of UW. This retrospective database analysis shows
that differences in outcome by preservation fluids are caused
by regional differences in donor, recipient and transplant
characteristics. These differences, rather than the used preser-
vation fluid, cause the difference in outcome. When adjusted
for these risk factors, no differences in graft survival exist be-
tween transplantations performed with livers that are pre-
served with either HTK or UW.ACKNOWLEDGMENTS
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